UC San Diego
SCHOOL OF MEDICINE

RISE UP:
***R**evolutionizing **I**nvestigations to **S**t**E**p **U**p **P**revention for Breast Cancers:*
November 1-3, 2024
San Francisco, California

This new, interdisciplinary conference focuses on a bold reimagining of breast cancer prevention and treatment through cross-disciplinary exchange of ideas and out-of-the-box thinking. We will focus on minimizing the long-term side effects associated with therapeutic interventions using early endpoints, recognizing that a key to better uptake in preventive therapies is better tolerability. An important goal of the meeting is to foster interdisciplinary approaches across the gynecology and oncology and primary care fields and build collaborations focused on reducing breast cancer incidence.

A primary goal of RISE UP is to consider breast cancer prevention across a woman's life course, and translate scientific findings to actionable, accessible medications and strategies to reduce breast cancer risk among individuals and communities. Currently, there is strong evidence that those who live in more impoverished areas often have more aggressive forms of breast cancer. We hope this meeting will spur new treatment and prevention strategies that will bring important options to those at most risk for breast cancer and who are diagnosed with the most aggressive disease. Through this multi-disciplinary conference, bringing together epidemiologists, policy makers, and more, we hope to present research that specifically examines the impact of deprivation, racism, environmental exposure burden, and place of residence on the etiology and incidence of breast cancer to better understand these disparities.

This conference is designed for women's health providers of all specialties, scientists, advocates, policymakers and innovators to RISE UP to the challenge of reducing breast cancer incidence and mortality in our lifetime

At the completion of the conference, participants should be able to:

- Identify new classifications and treatments for breast cancer.
- Discuss new ways to assess risk for breast cancer and what is available for risk reduction.
- Survey the potential for hormonal products as risk-reducing interventions for breast cancer.
- Analyze the impact of restricted access to reproductive services on the health and well-being of women.
- Create opportunities to lower the barriers to participation in trials through patient-centered design and strategies to make trials more accessible regardless of insurance.
- Identify the differences in biologic effects on breast tissue and other organs between selective estrogen receptor modulators and tissue specific estrogen complexes being studied for breast cancer risk reduction.
- Describe the amount of sustained weight/fat loss likely needed for significant breast cancer risk reduction and metabolic pathways impacted for breast cancer risk reduction.
- Evaluate the challenges and potential benefits in studying the GLP-1 and GIP receptor agonists for breast cancer risk reduction.
- Describe the impact of new restrictions on abortion since the Supreme Court's Dobbs decision, including the effects on people seeking services, on general obstetrical care, and on medical education.
- Examine potential common denominators for increased risk in maternal mortality and breast cancer in African American women.

Program Schedule/Agenda

Friday, November 1, 2024

12:00 PM-12:15PM	Welcome: *A Paradigm Shift in Women's Health: A Holistic View of hormone cycle control and breast cancer risk reduction* (Laura Esserman, MD, MBA (UC San Francisco))
12:15 PM-12:30PM	Keynote Address: *The Launch of the Birth Control Pill and How It Should Inform Decisions Today* (Liz Watkins, PhD (UC Riverside))
	Session 1: Tumor Classification in Optimizing Therapy and Outcomes
12:30 PM-12:30PM	Introduction: Laura van't Veer, PhD, UC San Francisco
12:30 PM-12:45PM	*Response Predictive Subtypes (RPS): origins, evolution, and future directions* (Denise Wolf, PhD (UC San Francisco))
12:45 PM-12:55PM	*Analysis of I-SPY2-990 Data to Reveal New Pathways of Resistance in Response Predictive Subtype-Negative and Response Predictive Subtype-Discordant Breast Cancers* (Tam Binh V. Bui, MSc, MD (UC San Francisco))
12:55 PM-1:05PM	*Improving risk stratification and prediction of response to neoadjuvant therapy (NAT) by serial monitoring of circulating tumor DNA (ctDNA) in high-risk early-stage breast cancer* (Mark Magbanua, PhD (UC San Francisco))
1:05 PM-1:15PM	*The steroid hormone receptor signature (SRS) in stage II/III triple negative breast cancer correlates with highly actionable functional protein drug target activation and is associated with early recurrence* (Julie Wulfkuhle (George Mason University))
1:15 PM-1:25PM	*Examining APOBEC3B in TCGA and ICGC Breast Cancer Datasets Reveals Altered Drug Metabolism Pathways* (Joel Pardo (University of Minnesota))
1:25 PM-1:40PM	*Diagnosis 2030: What AI Can (and Can't) do for you* (Sandy Borowsky, MD (UC Davis))
1:40 PM-2:00PM	Summary Panel (moderated by Lajos Pusztai, MD, DPhil (Yale), and Amy Delson, Patient Advocate)
	Session 2: Imaging as a Predictive Biomarker in Clinical Trials Early Endpoint
2:15 PM-2:20PM	Introduction (moderated by Nola Hylton, PhD (UCSF), Elissa Price, MD (UCSF), Diane Heditsian, Patient Advocate, Jan Tomlinson, Patient Advocate)
2:20 PM-2:45PM	*Ultrafast MRI in Post Treatment Assessment* (Yiming Gao, MD (NYU))
2:45 PM-2:55PM	Patient Perspectives (Jan Tomlinson, Patient Advocate, Diane Heditsian, Patient Advocate)
2:55 PM-3:02PM	*Temporal Changes in Mammographic Breast Density as a Predictive Biomarker across the Breast Cancer Continuum* (Gretchen Gierarch, PhD, MPH (NIH))
3:02 PM-3:09PM	*Real World Study of the Effect of T+Ai on Background Parenchymal Enhancement (BPE)* (Wayne Tilley, PhD (University of Adelaide))
3:09 PM-3:16PM	*Interim Results from a Multimodality Screening Program Reveal Low Recall Rates and Breast Cancer Detection in BRCA Mutation Carriers Undergoing Biannual DCE-MRI* (Hatice Basdag (University of Chicago))
3:16 PM-3:23PM	*Short-term declines in breast density by treatment-associated endocrine symptoms after tamoxifen therapy: Examining the role of CYP2D6 phenotype and tamoxifen metabolites* (Cody Ramin, PhD (Cedars Sinai Medical Center)
3:23 PM-3:30PM	*Validation of an MRI-Based Predictive Model for Treatment Tailoring in the I-SPY 2 Trial* (Wen Li, PhD (UC San Francisco))
3:30 PM-3:45PM	Panel Discussion of Speakers
3:45 PM-4:15PM	Break and Exhibitors Light Refreshments
4:15-6:30pm	**Session 3: Increasing Efficiency While Decreasing Toxicity of Local and Systemic Therapy (NOT FOR CME CREDIT)**
6:30 PM-7:30PM	**Poster Session #1 (NOT FOR CME CREDIT):** Tumor classifiers, imaging endpoints, toxicity reduction

Saturday, November 2, 2024

	Session 4: Risk Prediction and Biomarkers for Prevention Trials
8:00 AM-8:15AM	Introduction (Adetunji Toriola, MD, PhD, MPH (WUSTL))
8:15 AM-8:30AM	*Senescence-Based Deep Learning Predicts Breast Cancer Risk Using H&E Core Biopsy Images From Healthy Women* (Mark Powel, MD, MPH (Buck Institute for Research on Aging))
8:30 AM-8:45AM	*Predicting Risk of Future Breast Cancer based on Screening MRI Features* (Suleeporn Sujichantararat, PhD (University of Washington))
8:45 AM-9:00AM	*Stromal Inflammation as a Driver of Parity-related Breast Cancer Etiologic Heterogeneity: Implications for Precision Prevention in a Sub-Saharan African Population* (Mustapha Abubakar, MD, PhD (National Cancer Institute, NIH))
9:00 AM-9:15AM	*Characterizing the Immune and Non-immune Landscape of Premalignant and Preinvasive Breast Lesions* (Vagmi Luhar (National Cancer Institute))
9:15 AM-9:20AM	Advocate Presentation: Carmelita Austin-Schreher (Patient Advocate)
9:20 AM-9:30AM	Session Summary (Laura Fejerman, PhD (UC Davis))
	Session 5: Applying the Lessons of Breast Cancer Biology to Prevention
9:35 AM-9:40AM	Introduction (Carol Fabian, MD (University of Kansas))
9:40 AM-10:00AM	*PrevenNng Breast Cancer with Molecules TargeNng the Estrogen Receptor: SERMs, SERDs, and TSECs* (Barry Komm, PhD)
10:00 AM-10:08AM	*DCIS: RECAST - An Adaptive Platform Trial to Identify Women With Hormone Receptor Positive DCIS who are Candidates for Active Surveillance* (Kelly Hewitt, MD (University of Utah))
10:08 AM-10:16AM	*Refining tamoxifen dose for premenopausal breast cancer risk reduction (RENAISSANCE). A Phase II single-arm trial* (Seema Khan, MD (Northwestern University)
10:16 AM-10:24	*Beneficial effects of bazedoxifene plus conjugated estrogens (Duavee) on breast cancer risk and metabolic biomarkers in a rat model of obesity, menopause, and breast cancer* (Erin Giles, PhD (University of Michigan))
10:24 AM-10:45AM	*Breaking the Obesity-Breast Cancer Link: Diet, Drug and Surgical Strategies* (Stephen Hursting, PhD (University of North Carolina))
10:45 AM-10:53AM	*Resistance and aerobic Exercise for Prevention in women with Dense breasts (REP-D): A Trial in Progress* (Jennifer Ligibel, MD (Dana Farber Cancer Institute))
10:53 AM-11:01AM	*Time restricted Eating And Metformin (TEAM) in invasive breast cancer or DCIS: a randomized window of opportunity trial. Preliminary safety analysis* (Irene Maria Briata, PhD (E.O. Ospedali Galliera))
11:01 AM-11:09AM	*Low dose TamOxifen and LifestylE changes for bReast cANcer prevention (TOLERANT Study): Study Protocol of a Randomized Phase II Biomarker Trial in Women at Increased Risk for Breast Cancer* (Matteo Lazzeroni, MD (European Institute of Oncology IRCCS))
11:09 AM-11:30AM	Q&A, Summary, Persistence in Prevention Award
11:30 AM-1:15PM	**Poster Session #2 (NOT FOR CME CREDIT):** Prevention studies in progress, Turnaway study
	Session 6: The Consequences of the Dobbs Decision: A Look at the Impact in Women's Health
2:15 PM-2:45PM	*The Effect of the Dobbs Decision on Patients and Providers Nationally and in the Southeast* (Jamila Perritt, MD (Physicians for Reproductive Health))
2:45 PM-3:00PM	*Care Post-Roe Study: Documenting Poor Quality Care Since Dobbs* (Daniel Grossman, MD (UC San Francisco))
3:00 PM-3:15PM	*The Turnaway Study and End of Roe Study* (Diane Greene Foster, PhD (UC San Francisco))
3:15 PM-3:30PM	*Effects of Dobbs on Medical Education* (Josie Urbina, MD (UC San Francisco))
3:30 PM-3:45PM	Q&A and Discussion

	Session 7 Panel: Breast Cancer and Maternal Mortality Disparities in African American Women: Connection or Coincidence?
4:00 PM-4:05PM	Introduction (Andrea Jackson, MD, MAS (UC San Francisco))
4:05 PM-4:15PM	Infertility and Pelvic Floor Disorders in Black Women (Oluwateniola Brown, MD (Northwestern University))
4:15 PM-4:30PM	Obesity, Inflammation and Uterine Fibroids (Obianuju Sandra Madueke-Laveaux, MD, MPH (University of Chicago))
4:30 PM-4:35PM	Evolutionary trajectory of breast cancer in diverse populations (Olufunmilayo Olopade, MD (University of Chicago))
4:35 PM-4:45PM	Targeting inflammatory pathways in breast cancer (examples from I-SPY) (Frederick Howard, MD (University of Chicago))
4:45 PM-4:50PM	Advocate Perspective (Ricki Fairley, Patient Advocate)
4:50 PM-5:00PM	Panel Discussion (moderated by Olufunmilayo Olopade, MD (University of Chicago), Andrea Jackson, MD, MAS (UCSF), Ricki Fairley (Patient Advocate))
	Session 8: Improving Diversity in Clinical Trials
5:00 PM-5:05PM	Introduction (Sara Horton, MD (Howard University), Kim Rhoads, MD, MS, MPH (UC San Francisco))
5:05 PM-5:30PM	Case Study: ISPY 2 Trial and ACCESS Initiative (Priya Jayachandran, MD (University of Southern California), Dominic Zavala (University of Southern California))
5:30 PM-5:45PM	Financial Barriers and Insurance Coverage in Clinical Trials (Laura Esserman, MD, MBA (UC San Francisco), Dana Dornsife (Lazarex Cancer Foundation), Maimah Karmo (Patient Advocate)
5:45 PM-6:00PM	**Poster Session #3 (NOT FOR CME CREDIT)**: Environmental exposures, novel prevention strategies, risk prediction, risk factors

Sunday, November 3, 2024

7:00 AM-8:00AM	**Poster Session #4 (NOT FOR CME CREDIT): Cycle Control, Post-partum weaning, menopause control, modifiable risk factors**
8:00 AM-8:30AM	**Session 9:** Lecture: The Science of the Sex Hormone Ecosystem Across a Women's Lifetime (Carol Lange, PhD (University of Minnesota))
8:30 AM-8:35AM	**Session 10: Postpartum Breast Cancer: Opportunities for Improving Treatment and Prevention?** (Virginia Borges, MD (University of Colorado))
8:35 AM-8:40AM	Lynda Weatherby's Story (Lynda Weatherby, Patient Advocate)
8:40 AM-9:00AM	*Studies of postpartum breast cancer inform novel treatment options* (Traci Lyons,
9:00 AM-9:10AM	PhD ())
	Breastfeeding Attributable Risk of Triple Negative Breast Cancer in the US (Lajos
9:10 AM-9:20AM	Pusztai, MD, Dphil (Yale))
	PPBC Vit D Liver Metabolism (Pepper Schedin, PhD (Oregon Health Sciences
9:20 AM-9:30AM	University (OHSU))
	Identifying Gaps in Care Among Patients with Pregnancy and Post-Partum
9:30 AM-9:40AM	*Associated*
9:40 AM-9:50AM	*Breast Cancer* (Malcom Su, MD (University of Texas Southwestern))
	Lynda Weatherby's Story cont. (Lynda Weatherby, Patient Advocate)
9:50AM-10:15AM	Panel Discussion and Q&A
10:15AM-11:15AM	**Session 11: Making Preven9on and Holis9c Care a Priority in Women's Health (NOT FOR CME CREDIT)**
11:15AM-12:45PM	**Session 12: Ideas to Implementa9on: Incorpora9ng Breast Cancer Preven9on into a Holistic Approach to Women's Health(NOT FOR CME CREDIT)**

Planning Committee

Alexander Borowsky, MD
Professor of Pathology and Laboratory Medicine
University of California, Davis

Andrea Jackson, MD
Edward C. Hill, M.D., Endowed Chair in Obstetrics, Gynecology and Reproductive Sciences
University of California, San Francisco

Carol Lange, PhD
Professor of Medicine (Division of Hematology, Oncology, and Transplantation) and Pharmacology
Tickle Family Land Grant Endowed Chair of Breast Cancer Research
Masonic Cancer Center Associate Director of Basic Science
University of Minnesota

Daniel Grossman, MD
Professor and Vice Chair of Advocacy
Department of Obstetrics, Gynecology and Reproductive Sciences
Director, Advancing New Standards in Reproductive Health (ANSIRH)
University of California, San Francisco

Diane Heditsian, BA
Research, Patient and Policy Breast Cancer Advocate
Founder/CEO, deClarity
UCSF Breast Science Advocacy Core

Douglas Yee, MD
Director, Masonic Cancer Center
Professor of Medicine and Pharmacology
Division of Hematology, Oncology, and Transplantation
University of Minnesota

Olufunmilayo Olopade, MBBS
Walter L. Palmer Distinguished Service Professor of Medicine
Professor of Human Genetics
Director, Center for Clinical Cancer Genetics and Global Health
University of Chicago

Francesca Leung

Judy Garber, MD, MPH
Chief, Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute
Professor of Medicine
Susan F. Smith Chair, Dana-Farber Cancer Institute
Harvard Medical School

Kelly Adduci, MPH

Laura Esserman, MD, MBA
Director, UCSF Breast Care Center
Professor of Surgery and Radiology
Alfred A. de Lorimier Endowed Chair in General Surgery
University of California, San Francisco

Laura Fejerman, PhD

Nandini Seth

Sara Horton, MD
Executive Director of Access and Diversity
Quantum Leap Healthcare Collaborative

Silvia Formenti, MD
Professor of Radiation Oncology and Medicine
Chair, Radiation Oncology
Sandra and Edward Meyer Professor of Cancer Research
Weill Cornell Medical College

Taylor Glatt, BS

Faculty/Presenter List

Mustapha Abubakar, MD, PhD
Earl Stadtman Investigator
National Institute of Cancer

Hatice Basdag
Clinical Research Coordinator
University of Chicago

Virginia Borges MD
Professor, Medicine-Medical Oncology
University of Colorado Medicine

Sandy Borowsky, MD
Professor, Director of Molecular Diagnostics
University of California, Davis

Irene Maria Briata, PhD
Study Coordinator
E.O. Ospedali Galliera

Oluwateniola (Teni) Brown, MD
Assistant Professor of Obstetrics and Gynecology
Northwestern University

Tam Binh V. Bui, MSc, MD
Researcher in Laboratory Medicine
University of California, San Francisco

Andrea De Censi, MD
Professor, Medical Oncology
Ospedali Galliera

Amy Delson
Patient Advocate
University of California, San Francisco

Dana Dornsife
Founder, Chief Mission and Strategy Officer
Lazarex Foundation

Laura Esserman, MD, MBA
Director, UCSF Carol Franc Buck Breast Care Center
University of California, San Francisco

Mikael Eriksson, PhD
Epidemiologist
Karolinska Instituet

Carol Fabian, MD
Director, Breast Cancer Prevention and Survivorship Research Center
University Distinguished Professor
Professor, Medical Oncology and Internal Medicine
University of Kansas Medical Center;

Laura Fejerman, PhD
Professor, Medicine and Public Health Sciences
University of California, Davis

Silvia Formenti, MD
Chair, Radiation Oncology
Professor, Medicine
Weill Cornell Medicine

Diana Greene Foster, PhD
Director of Research, Advancing New Standards in Reproductive Health (ANSIRH)
University of California, San Francisco

Yiming Gao, MD
Associate Professor
New York University

Judy Garber, MD, MPH
Chair and Chief of the Division of Cancer Genetics and Prevention
Dana-Farber Cancer Institute

Gretchen Gierach, PhD, MPH
Senior Investigator and Director
National Institute of Cancer

Erin Giles, PhD
Assistant Professor
University of Michigan

Fabiana Gregucci, MD
Associate Researcher
Weill Cornell Medicine

Daniel Grossman, MD
Professor
Director, Advancing New Standards in Reproductive Health
University of California, San Francisco

Diane Heditsian
Patient Advocate
University of California, San Francisco

Kelly Hewitt, MD
Associate Professor
University of Utah

Sara Horton, MD
Executive Director of Access and Diversity
Quantum Leap Healthcare

Frederick Howard, MD
Assistant Professor of Medicine
University of Chicago

Stephen Hursting, PhD
Professor in the Department of Nutrition and the Lineberger Comprehensive Cancer Center
University of North Carolina - Chapel Hill

Nola Hylton, PhD
Professor, Department of Radiology and Biomedical Imaging
Director, Breast Imaging Research Group
University of California, San Francisco

Priya Jayachandran, MD
Assistant Professor of Clinical Medicine at Keck
Director of Breast Medical Oncology and Genomics at the LAC+USC Medical Center.
University of Southern California

Andrea Jackson, MD, MAS
Chair, Obstetrics, Gynecology and Family Planning
University of California, San Francisco

Maimah Karmo
Patient Advocate
TigerLily Foundation

Seema Khan, MD
Professor of Surgery
Northwestern University

Barry Kom, PhD
Independent Scientific Advisor
Komm-Sandin Pharma Consulting

Andrea Lacroix, PhD
University of California, San Diego
Director of UCSD's Women's Health Center of Excellence

Carol Lange, PhD
Professor, Medicine
Associate Director for Basic Sciences
University of Minnesota Masonic Cancer Center

Matteo Lazzeroni, MD
Senior Oncologist
European Institute of Oncology IRCCS

Wen Li, PhD
Associate Researcher
University of California, San Francisco

Jennifer Ligibel, MD
Director, Zakim Center for Integrative Therapies and Healthy Living
Dana-Farber Cancer Institute

Catherine Lu Dugan
Medical Student
Keck School of Medicine of USC

Vagmi Luhar
Pre-Baccalaureate Research Fellow
National Institute of Cancer

Traci Lyons, PhD
Associate Professor
University of Colorado Medicine

Obianuju Sandra Madueke-Laveaux, MD, MPH
Associate Professor of Obstetrics and Gynecology
Director, Center for the Advanced Treatment and Research (CATeR) of Uterine Fibroids
University of Chicago

Mark Magbanua, PhD
Professional Researcher
University of California, San Francisco

Bruce Mann, MBBS
Professor of Surgery
University of Melbourne

Jane Mortimer
Patient Advocate
University of California, San Francisco

Olufunmilayo Olopade, MD
Professor, Human Genetics
Director, Center for Clinical Cancer Genetics and Global Health
University of Chicago Medicine

Joel Pardo
Graduate Student
University of Minnesota

Jamila Perritt, MD
OB/GYN
Physicians for Reproductive Health

Nicolas Prionas, MD
Radiation Oncologist
University of California, San Francisco

David Portman, MD
Chief Executive Officer
Sermonix Pharmaceuticals

Mark Powell, MD, MPH
Visiting Scientist
Buck Institute for Research on Aging

Elissa Price, MD
Profesoor, Clinical Radiology
University of California, San Francisco

Lajos Pusztai, MD, Dphil
Professor of Medicine (Medical Oncology)
Yale School of Medicine

Cody Ramin, PhD
Assistant Professor
Cedars Sinai Medical Center

Kim Rhoads, MD, MS, MPH
Associate Professor of Epidemiology & Biostatistics
Director, Office of Community Engagement
Associate Director for Community Outreach and Engagement, UCSF Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco

Hope Rugo, MD, FASCO
Professor, Medicine Division of Hematology and Oncology
University of California, San Francisco

Pepper Schedin, PhD
Professor
Oregon Health Sciences University

Malcolm Su, MD
Resident
University of Texas Southwestern

Suleeporn Sujichantararat, PhD
Postdoctoral Scholar
University of Washington

Wayne Tilley, PhD
Director of the Dame Roma Mitchell Cancer Research Laboratories
University of Adelaide

Jan Tomlinson
Patient Advocate
University of California, San Francisco

Adetunji Toriola MD, PhD, MPH
Professor, Surgery
Washington University Saint Louis

Josie Urbina, MD
Assistant Professor
University of California, San Francisco

Elizabeth Watkins, PhD
Provost and Executive Vice Chancellor
University of California, Riverside

Lynda Weatherby
Patient Advocate
Metastatic Breast Cancer Alliance

Denise Wolf, PhD
Research Scientist
University of California, San Francisco

Julie Wulfkuhle
Research Professor
George Mason University

Douglas Yee, MD
Director of Masonic Cancer Center
University of Minnesota

Dominic Zavala
Research Coordinator
University of Southern California

Elad Ziv, MD
Professor, Medicine
University of California, San Francisco

Disclosure Summary

It is the policy of University of California San Diego School of Medicine Continuing Professional Development to ensure that the content of accredited continuing education and related materials is accurate, balanced, objective, and scientifically justified. Education must be free of the influence or control of ineligible companies, and protect learners from promotion, marketing, and commercial bias. All persons in a position to control the content of accredited continuing education must disclose all financial relationships held with ineligible companies, prior to assuming a role in the activity. Those relationships deemed relevant to the education are mitigated prior to the activity through one of the following strategies, depending on the nature of relationship and the role of the person: 1) divesting the financial relationship, 2) altering the individual's control over content, and/or 3) validating the planning decisions and/or content through independent peer review. All relevant financial relationships are mitigated prior to the activity and mitigation strategies and necessary steps for implementation are communicated to individuals prior to them assuming their role in the activity. Persons who refuse or fail to disclose are disqualified from participating in the activity. Activities are evaluated by participants and peer reviewers to determine if the content was free of bias and met acceptable scientific standards. This information is considered in future activity planning. ***All relevant financial relationships and the nature of those relationships are noted below. All relevant financial relationships have been mitigated.***

Faculty Member Name	Role in Activity	Name of Ineligible Company(ies)/Nature of Relationship(s)
Virginia Borges	Session Chair	Consulting fees paid to me for running ad boards, moderating lectures, speaking/presenting fees: AstraZeneca, SeaGen/Pfizer, Olema, Gilead. Travel support for presenting: Olema; Receives funding to her institution for clinical trials: AstraZeneca, Gilead, SeaGen/Pfizer, Olema.
Dana Dornsife	Speaker	Honorarium - Bristol Meyer Squibb
Mikael Eriksson	Speaker	iCAD Medical Patent License
Laura Esserman	Organizing Committee Member	Investigator initiated trial for high risk DCIS funded by Moderna for Dcis phase 1 study
Silvia Formenti	Session Chair	A consultant for AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Elekta, EMD Serono/Merck, Genentech/Roche, GlaxoSmithKline, Janssen, Medimmune, Merck US, Nanobiotix, Regeneron, Varian, ViewRay and receives research support from Arcus, Bristol Myers Squibb, Celldex, Merck, Regeneron, and Varian.
Judy Garber	Organizing Committee Member	Consulting or Advisory Role: Novartis, Kronos Bio, GV20 Therapeutics, Belharra Therapeutics, Inc, Earli, Inc Research Funding: Novartis, Ambry Genetics, InVitae, Amgen Other Relationship: AACR, Diana Helis Henry Medical Foundation, James P. Wilmot Foundation, Adrienne Helis Malvin Medical Research Foundation, Breast Cancer Research Foundation, Facing our Risk of Cancer Empowered
Frederick Howard	Speaker	Consultant for Novartis and Leica Biosystems
Barry Komm	Presenter	Consultant for Sermonix Pharmaceuticals
Obianuju Sandra Madueke-Laveaux	Presenter	Honoraria - Intuitive Surgical, PI Investigator - Sumitomo Pharmaceutical

Olufunmilayo Olopade	Session Chair	Financial relationships with CancerIQ, 54gene, HealthWell Solutions, and Tempus, as well as research funding from Ayala Pharmaceuticals, Cepheid, Color Genomics, Novartis, and Genentech
Lajos Pusztai	Session Chair	L.P. has received consulting fees and honoraria for advisory board participation from Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Stemline-Menarini, GlaxoSmithKline, Genentech/Roche, Personalis, Daiichi, Natera, Agendia, Exact Sciences, Radionetics, and institutional research funding from Seagen, GlaxoSmithKline, AstraZeneca, Merck, Pfizer and Bristol Myers Squibb
Wayne Tilley	Speaker	Scientific Advisor for Ellipses Pharma Limited and Havah Therapeutics
Hope Rugo	Session Chair	Consulting roles with Chugai, Puma, Sanofi, Napo, and Mylan; Reports institutional research support from AstraZeneca, Daiichi Sankyo, F. Hofmann-La Roche AG/Genentech, Gilead Sciences, Lilly, Merck & Co., Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics, OBI Pharma, Ambrx and Greenwich Pharma
Julie Wulfkuhle	Presenter	Reports other from Theralink Technologies outside the submitted work; in addition, J. Wulfkuhle has a patent to 10,823,738-B2 issued, licensed, and with royalties paid.
Douglas Yee	Organizing Committee	Consulting fees from Martell Diagnostics; and honoraria and travel for speaking at the 'International Breast Cancer Conference'

Persons in control of content of this educational activity who are not specifically identified by name above, such as (but not limited to) course directors, faculty, CME staff, planners, editorial staff, peer reviewers, and CME committee reviewers do not have any relevant financial relationships.

This educational activity may contain discussion of unlabeled and/or investigational uses of agents that are not approved by the FDA. Please consult the prescribing information for each product. The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views of the University of California San Diego School of Medicine.

Accreditation

The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of California San Diego School of Medicine designates this live activity for a maximum of ***11.5*** *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Surgery (ABS): Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirement of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit

Cultural & Linguistic Competency and Implicit Bias:

Continuing medical education (CME) providers are required by state Assembly Bills 1195 and 241, and the standards created by the California Medical Association (CMA), to include components that address cultural and linguistic competency and implicit bias in CME activities. The planners and presenters of this activity has been asked to provide meaningful consideration of these standards in the selection and presentation of content. Additional information and resources are available on the UC San Diego CME website (cpd.ucsd.edu)

Commercial Support Acknowledgement

We would like to thank the following companies for providing educational support of this activity:

AstraZeneca

Exhibitor Acknowledgement

We would like to acknowledge the following companies and organizations for exhibiting at this conference.

Atossa
Exai Bio

Additional Support Acknowledgement

We would like to thank the following companies for providing educational support of this activity:

National Cancer Institute
California Breast Cancer Research Program
University of California, San Francisco School of Medicine
Breast Cancer Research Foundation